Sarepta Therapeutics Inc (NASDAQ:SRPT) was upgraded by investment analysts at Vetr from a “strong sell” rating to a “sell” rating in a research report issued on Tuesday. The firm currently has a $17.28 target price on the stock. Vetr‘s price target would indicate a potential downside of 10.97% from the company’s previous close. Shares of […]
